We are live on
!
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter
Est. Return
+13.55%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$342M
AUM Growth
-$21.8M
(-6%)
Cap. Flow
-$22.5M
Cap. Flow
% of AUM
-6.57%
Top 10 Holdings %
Top 10 Hldgs %
41.65%
Holding
72
New
20
Increased
8
Reduced
15
Closed
12
Top Buys
| 1 |
APLS
Apellis Pharmaceuticals
APLS
|
+$11.2M |
| 2 |
Rocket Pharmaceuticals
RCKT
|
+$8.19M |
| 3 |
GH Research
GHRS
|
+$8.14M |
| 4 |
ALLK
Allakos
ALLK
|
+$7.59M |
| 5 |
TCRR
TCR2 Therapeutics Inc. Common Stock
TCRR
|
+$6.74M |
Top Sells
| 1 |
TRIL
Trillium Therapeutics Inc.
TRIL
|
+$12.1M |
| 2 |
Biogen
BIIB
|
+$11.3M |
| 3 |
Fate Therapeutics
FATE
|
+$10.6M |
| 4 |
RAPT
RAPT Therapeutics
RAPT
|
+$10.6M |
| 5 |
TG Therapeutics
TGTX
|
+$6.98M |
Sector Composition
| 1 | Healthcare | 86.75% |
| 2 | Financials | 1.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CALL
iShares Russell 2000 ETF
IWM
$82.2B
| $21.9M | 6.4% |
+100,000
| New | +$22.2M |
|
2
Ascendis Pharma A/S
ASND
$17.1B
| $19.1M | 5.59% |
120,000
-15,000
| -11% | -$2.05M |
|
3
Iovance Biotherapeutics
IOVA
$2.23B
| $17.3M | 5.05% |
700,000
+250,000
| +56% | +$5.89M |
|
4
Celldex Therapeutics
CLDX
$2.77B
| $13.8M | 4.03% |
255,000
-30,000
| -11% | -$1.41M |
|
5
Cogent Biosciences
COGT
$6.68B
| $12.6M | 3.69% |
1,500,000
-100,000
| -6% | -$766K |
|
6
Arvinas
ARVN
$517M
| $12.3M | 3.6% |
150,000
-55,000
| -27% | -$4.86M |
|
7
Xenon Pharmaceuticals
XENE
$6.6B
| $12.1M | 3.53% |
790,000
-60,000
| -7% | -$1.04M |
|
|
ISEE
8
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $11.8M | 3.44% |
725,000
| – | – |
|
9
Syndax Pharmaceuticals
SNDX
$2.02B
| $11M | 3.21% |
575,000
-300,000
| -34% | -$5M |
|
|
MRTX
10
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $10.6M | 3.1% |
60,000
+10,000
| +20% | +$1.61M |
|
|
11
Rocket Pharmaceuticals
RCKT
$376M
| $10.5M | 3.06% |
350,000
+225,000
| +180% | +$8.19M |
|
|
ALLK
12
DELISTED
Allakos
ALLK
| $9M | 2.63% |
+85,000
| New | +$7.59M |
|
|
13
GH Research
GHRS
$1.97B
| $8.82M | 2.58% |
+400,000
| New | +$8.14M |
|
14
Kura Oncology
KURA
$964M
| $7.96M | 2.33% |
425,000
-275,000
| -39% | -$5.18M |
|
|
RAPT
15
DELISTED
RAPT Therapeutics
RAPT
| $7.76M | 2.27% |
31,250
-40,000
| -56% | -$10.6M |
|
|
CYPH
16
Cypherpunk Technologies Inc
CYPH
$75.4M
| $6.62M | 1.93% |
+165,000
| New | +$3.1M |
|
|
APLS
17
DELISTED
Apellis Pharmaceuticals
APLS
| $6.59M | 1.93% |
+200,000
| New | +$11.2M |
|
18
CALL
BeyondSpring
BYSI
$53M
| $6.3M | 1.84% |
+400,000
| New | +$7.19M |
|
19
Aldeyra Therapeutics
ALDX
$102M
| $6.15M | 1.8% |
700,000
+100,000
| +17% | +$918K |
|
20
Viridian Therapeutics
VRDN
$1.99B
| $5.76M | 1.68% |
350,000
| – | – |
|
21
VistaGen Therapeutics
VTGN
$9.4M
| $5.48M | 1.6% |
66,667
| – | – |
|
22
Atea Pharmaceuticals
AVIR
$390M
| $5.26M | 1.54% |
+150,000
| New | +$4.16M |
|
23
Relmada Therapeutics
RLMD
$550M
| $5.24M | 1.53% |
+200,000
| New | +$5.35M |
|
24
Aclaris Therapeutics
ACRS
$793M
| $4.95M | 1.45% |
275,000
+25,000
| +10% | +$401K |
|
|
APLS
25
CALL
DELISTED
Apellis Pharmaceuticals
APLS
| $4.94M | 1.45% |
+150,000
| New | +$8.43M |
|
Similar funds
SF
AFS
SFA
E
OHCM
MC
BRA
S
Ghost Tree Capital's Q3 2021 Portfolio in Review
As of Q3 2021, Ghost Tree Capital held 72 positions worth $342M, down 6% from $364M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Ghost Tree Capital withdrew a net $22.5M in Q3 2021, closing 12 positions and reducing 15 holdings. Its most notable exit was Trillium Therapeutics Inc., an estimated $12.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 85% a quarter earlier, followed by Financials.
Against the trend, Ghost Tree Capital opened a new position in Apellis Pharmaceuticals worth $6.59M.
- Ghost Tree Capital's largest Q3 2021 buy was Apellis Pharmaceuticals: 200,000 shares worth $6.59M.
- Ghost Tree Capital added most to Rocket Pharmaceuticals in Q3 2021, an estimated $8.19M increase.
- Ghost Tree Capital's biggest Q3 2021 reduction was Fate Therapeutics, cutting an estimated $10.6M.
- Ghost Tree Capital fully exited Trillium Therapeutics Inc. in Q3 2021, selling an estimated $12.1M.
- Ghost Tree Capital's ten largest holdings make up 42% of its $342M portfolio in Q3 2021.
- Ghost Tree Capital opened 20 new positions and closed 12 in Q3 2021.
- Ghost Tree Capital's portfolio value fell 6% quarter-over-quarter to $342M.
Based on Ghost Tree Capital's 13F filing for Q3 2021, filed 15 Nov 2021.